Entera Bio

ENTX · NASDAQ

$3.02+$0.08 (+2.72%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.94

About ENTX

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Employees: 20
Headquarters: Jerusalem
Listed: Jun 28, 2018
Sector: Health Care
Industry: Biotechnology
Website: enterabio.com

Leadership

Entera Bio executives
Name	Title	Since	Age
Geno Germano	—	—	65
Miranda Toledano	—	2018	48
Dana Yaacov-Garbeli	—	—	38
Hillel Galitzer	—	—	43
Ramesh Ratan	—	—	72
Arthur Santora	—	—	71
Roger Garceau	—	2016	71
Sean Ellis	—	—	47
Yonatan Malca	—	—	56
Ron Mayron	—	—	62
Steven Rubin	—	—	65
Haya Taitel	—	—	60

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Entera Bio suppliers and customers
Company	Relationship	Country	Correlation
Oramed Pharmaceuticals ORMP	Supplier and customer	US	0.50
Amgen AMGN	Supplier and customer	US	0.01

Similar companies

Companies in the same industry as Entera Bio

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.